Year All202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment Jun 02, 2024 Read More BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology May 14, 2024 Read More ORLADEYO® (berotralstat) Approved in Mexico May 13, 2024 Read More BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat) May 09, 2024 Read More BioCryst to Present at Upcoming Investor Conferences May 07, 2024 Read More BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update May 06, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 Read More BioCryst to Report First Quarter 2024 Financial Results on May 6 Apr 22, 2024 Read More BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency Apr 17, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 03, 2024 Read More
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment Jun 02, 2024 Read More
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology May 14, 2024 Read More
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat) May 09, 2024 Read More
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update May 06, 2024 Read More
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency Apr 17, 2024 Read More